We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies

Tel4.3

Telmisartan Research

Mostly mechanism / observationalLimited safety

7 peer-reviewed studies

What the evidence says

Mostly mechanism / observational

Most Telmisartan studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.

Most evidence is from high-quality meta-analyses and randomised trials published 2008–2018 with a typical study size of 20,332 participants.

Based on 7 studies · 1 meta-analysis · 5 RCTs · 77,552 total participants

Confidence

High

By outcome

Heart, blood pressure & stroke
Mostly mechanism / observational3 studies
Glucose, insulin & metabolic
Mostly mechanism / observational3 studies
Kidney & renal health
Too few graded studies1 study
Aging & healthspan (emerging)
Too few graded studies1 study
Safety profile
Too few graded studies1 study

Older research base

Newest study from 2018 · Latest meta-analysis: 2018

200820132018

1RCTn=25,620 · very large study2008

Telmisartan was non-inferior to ramipril for major cardiovascular events, but the combination of the two increased adverse events without added benefit.

ONTARGET Investigators, Yusuf, Teo, Pogue, Dyal, Copland · The New England journal of medicine (2008)

ONTARGET randomized 25,620 high-vascular-risk patients to ramipril, telmisartan, or both
Telmisartan was non-inferior (not superior) to the ACE inhibitor ramipril for the composite of CV death, MI, stroke, or HF hospitalization
Counter-evidence: the combination arm caused more hypotension, syncope, and renal dysfunction without added benefit

View source

2RCTn=20,332 · very large study2008

Telmisartan initiated soon after an ischemic stroke did not significantly lower the rate of recurrent stroke.

Yusuf, Diener, Sacco, Cotton, Ounpuu, Lawton · The New England journal of medicine (2008)

PRoFESS randomized 20,332 patients to telmisartan or placebo soon after an ischemic stroke
Telmisartan did NOT significantly reduce the primary outcome of recurrent stroke
Best counter-evidence: a large, clean negative trial capping the cerebrovascular-prevention claim

View source

3RCTn=25,620 · very large study2008

The combination of telmisartan and ramipril worsened major renal outcomes despite reducing proteinuria.

Mann, Schmieder, McQueen, Dyal, Schumacher, Pogue · Lancet (London, England) (2008)

Prespecified ONTARGET renal analysis of the same 25,620 patients
Combination ARB+ACE therapy increased the composite of dialysis, doubling of serum creatinine, and death versus monotherapy
Counter-evidence: dual RAS blockade is harmful to the kidney despite lowering proteinuria — telmisartan should not be combined with an ACE inhibitor

View source

4RCTn=5,926 · very large study2008

In ACE-inhibitor-intolerant patients, telmisartan was well tolerated but had only a modest, non-significant effect on the primary cardiovascular composite.

TRANSCEND Investigators, Yusuf, Teo, Anderson, Pogue, Dyal · Lancet (London, England) (2008)

TRANSCEND randomized 5,926 ACE-inhibitor-intolerant high-risk patients to telmisartan or placebo
Telmisartan was well tolerated and reduced a secondary composite, but did not significantly reduce the primary CV-death/MI/stroke/HF outcome
Extends telmisartan as the RAS option for patients who cannot tolerate ACE inhibitors

View source

5Meta-Analysis2018

Pooled across randomized trials, telmisartan improved insulin resistance compared with other angiotensin-receptor blockers.

Wang, Qiao, Han, Rong, Wang, Xue · American journal of therapeutics (2018)

Systematic review and meta-analysis of RCTs comparing telmisartan with other ARBs
Telmisartan improved insulin resistance (HOMA-IR) more than comparator ARBs, attributed to partial PPARγ activation
Quantifies the metabolic edge that distinguishes telmisartan within its class

View source

6RCTn=54 · small study2011

High-dose telmisartan induced monocytic PPARγ target genes in patients with the metabolic syndrome, confirming in-human PPARγ engagement.

Bähr, Tretter, Krüger, Stark, Schimkus, Unger · Hypertension (Dallas, Tex. : 1979) (2011)

Randomized, double-blind, placebo-controlled trial of telmisartan 80 and 160 mg/day in 54 metabolic-syndrome patients
High-dose telmisartan increased monocytic PPARγ target-gene expression (CD36, CD163)
Direct human evidence that telmisartan engages the PPARγ pathway — the mechanistic basis for its metabolic effects

View source

7Review2008

Telmisartan also activates PPARγ — an established antidiabetic drug target — as a selective modulator without the fluid retention and weight gain of conventional thiazolidinediones.

Kurtz · Nature clinical practice. Cardiovascular medicine (2008)

Review establishing telmisartan as an AT1 blocker that additionally activates PPARγ
As a selective PPARγ modulator it improves lipid/glucose metabolism without full-agonist fluid retention or weight gain
Frames the dual-mechanism rationale behind telmisartan's metabolic and geroscience interest

View source

View in Research Library

Telmisartan Research

Mostly mechanism / observational

Telmisartan, ramipril, or both in patients at high risk for vascular events.

Telmisartan to prevent recurrent stroke and cardiovascular events.

Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial.

Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial.

Telmisartan Improves Insulin Resistance: A Meta-Analysis.

High-dose treatment with telmisartan induces monocytic peroxisome proliferator-activated receptor-γ target genes in patients with the metabolic syndrome.

Beyond the classic angiotensin-receptor-blocker profile.